Zhongteng Tech: National High-Tech Enterprise with patents in multiple countries. Specializing in night vision/optical products, we deliver low-light/HD solutions for global outdoor (hunting, camping, sports) & professional scenarios (customs, oil depots, fire rescue). One-stop service, “Integrity & Win-win”, leading low-light imaging.
Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd.
Zhaoke Ophthalmology Limited (SEHK: 6622) Company Overview: Founded in 2017, Zhaoke Ophthalmology Limited is a leading ophthalmic pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of therapies that address significant unmet medical needs in the field of ophthalmology. Headquartered in Guangzhou, China, Zhaoke Ophthalmology is committed to improving visual health through innovative scientific research and cutting-edge technology. Mission: Our mission is to enhance the quality of life for patients by providing advanced and effective treatments for eye diseases. We strive to become a global leader in ophthalmology by delivering high-quality, accessible, and affordable eye care solutions. Research and Development: Zhaoke Ophthalmology boasts a comprehensive drug pipeline with 26 candidates targeting major ocular indications affecting both the front and back of the eye. Our R&D efforts are focused on developing innovative therapies for conditions such as dry eye disease, glaucoma, age-related macular degeneration, diabetic retinopathy, and other retinal diseases. We leverage both in-house development and strategic in-licensing to build a robust portfolio of ophthalmic treatments. Manufacturing Capabilities: Our state-of-the-art manufacturing facility in Nansha, Guangzhou, is equipped with advanced technology and adheres to the highest standards of quality and compliance. This facility enables us to efficiently produce both innovative and generic ophthalmic drugs, ensuring a reliable supply of high-quality products to meet the growing demand. Strategic Partnerships: Zhaoke Ophthalmology actively collaborates with leading domestic and international pharmaceutical companies to accelerate the development and commercialization of our products. These strategic partnerships enhance our capabilities and expand our reach in the global market. Market Presence: Listed on the Main Board of the Hong Kong Stock Exchange since April 2021, Zhaoke Ophthalmology has established a strong market presence and continues to grow its footprint in the ophthalmic pharmaceutical industry. Our experienced marketing team is dedicated to promoting our products and educating healthcare professionals about the benefits of our therapies. Commitment to Innovation: Innovation is at the core of Zhaoke Ophthalmology’s operations. We are committed to advancing the field of ophthalmology through continuous research and development, ensuring that our therapies address the evolving needs of patients and healthcare providers.
Xuxin (HongKong) Biotechnology Co., Limited
Xu Xin (Hong Kong) Biotechnology Co., Ltd. is a high-tech enterprise located in the Hong Kong Science Park, specializing in AI-driven research and development on innovative RNA-targeted therapy. The company is committed to addressing the unmet clinical needs in genetic diseases, neurological disorders, chronic diseases, and other therapeutic areas, and is dedicated to advancing the development of precision medicine through cutting-edge technologies. The company possesses a world-first RNA precision editing technology platform, which includes the world’s largest ADAR substrate editing library, an RNA fragment excising tool, and the AI-driven ATOMIC platform. These breakthrough innovations provide strong support and assurance for the company’s research and development of novel drugs. Through these top-notch technologies, the company is able to overcome the limitations of traditional small-molecule and biologic drugs, and to address key therapeutic challenges such as frameshift mutation diseases, single-point mutation genetic diseases, metabolic diseases and Immuno-oncology diseases. At the same time, our technical strategies ensure to avoid the irreversible off-target safety risks associated with DNA-level gene editing therapies.
Xiaomo Biotech Limited
Xiaomo Biotech is an expert on RNA biosynthesis. Our green biomanufacturing technology produces highly potent, specific, and cost-effective siRNAs (to kilograms) for various RNAi applications including gene knockdown in mammalian cells, high-throughput RNAi screen and RNAi pesticide. Xiaomo is committed to developing cutting-edge biotech products based on RNA interference (RNAi), a natural process which uses small interfering RNAs (siRNAs) to silence target genes in a precise manner. Xiaomo possesses a revolutionary RNAi platform technology known as the ‘prokaryotic siRNA’ (pro-siRNA) technology. The pro-siRNA technology uses bacteria as siRNA ‘factory’ instead of using chemical synthesis. This unique biomanufacturing method enables cost-effective and environmentally friendly production of highly effective siRNAs on a massive scale. Xiaomo has the capacity to produce siRNAs in gram to kilogram scales using bacterial fermentation. Xiaomo has also developed a customized high-throughput RNAi screen technique to identify potential therapeutic target genes in a disease, that could lead to the development of novel RNAi therapeutics. Currently, Xiaomo is offering various biomanufactured siRNA and RNAi library products to the R&D market. Xiaomo’s R&D efforts focus on developing first-in-class RNA pesticides for important crop pests including fungi, insects and nematodes. The ultimate goal of Xiaomo is to provide effective and affordable RNAi solutions for improving both human health and agricultural health. Xiaomo Biotech (www.xiaomobio.com) was founded at Hong Kong Science Park in 2019. We have recently established R&D and production sites in Shanghai Zhangjiang and Suzhou Kunshan China.
WEO Design Concept Limited
PROJECT DESIGN & CONTRACTING
Webuild Tech Limited
We focus on IoT, AI, and intelligent sensing, developing core capabilities in perception, spatial capture, and real-time computing. At CES, we present our Panorama Intelligent Mobile Device, a portable AI system that delivers high-resolution panoramic capture, real-time AI processing, and immersive visual experiences for creators and user
Vcare Vision Technology Limited
Vcare prioritizes research to ensure safe and effective solutions. Leveraging advanced knowledge in VR technology & vision care, we develop a device with a lens module with vari-focal mechanism & custom software. This meets individual visual needs without manual adjustments for vision training of myopia, amblyopia & strabismus.